EVALUATION OF INSULIN GLARGINE AND EXENATIDE ALONE AND IN COMBINATION: A RANDOMIZED CLINICAL TRIAL WITH CONTINUOUS GLUCOSE MONITORING AND AMBULATORY GLUCOSE PROFILE ANALYSIS.

Carlson AL, Mullen DM, Mazze R, Strock E, Richter S, Bergenstal RM

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 Apr 2019Cited by 8 (Europe PMC)

PMID30995433DOI10.4158/ep-2018-0177PepBankPUB-30995433

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the glargine-exenatide combination reduced A1C from 7.6 to 6.2%.
In plain wordsIn adults with type 2 diabetes, glargine plus exenatide lowered A1C from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C with initial combination
Study
n: not reported in source
Comparator
baseline
Outcome group
Glycemic control · Metabolic and weight
Measurements
A1C
7.6%
glargine plus exenatide, baseline
A1C
6.2%
glargine plus exenatide, end of study
Source sentences
Summary
Decreases in A1C were: 7.6 to 6.2% for Iglar + GLP-1, 7.5 to 6.6% for Iglar, and 7.5 to 6.4% for GLP-1.
3 context sentences(design, population, supporting numbers)
Summary · context
Open-label, randomized, parallel-arm study of adults with type 2 diabetes naïve to both insulin and glucagon-like peptide 1 (GLP-1) agonist who were not at A1C goal despite treatment with metformin.
Summary · context
Subjects were randomized to treatment with glargine (Iglar), exenatide (GLP-1), or combination of glargine and exenatide (Iglar + GLP-1).
Summary · context
At midpoint, those not at A1C target had the second medication added; those on Iglar + GLP-1 continued therapy optimization.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3099543301
02HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the initial exenatide arm reduced A1C from 7.5 to 6.4%, with protocol-directed intensification.
In plain wordsIn adults with type 2 diabetes, the initial exenatide regimen lowered A1C from baseline, with possible addition of insulin.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C with initial exenatide regimen
Study
n: not reported in source
Comparator
baseline
Outcome group
Glycemic control · Metabolic and weight
Measurements
A1C
7.5%
initial exenatide arm, baseline
A1C
6.4%
initial exenatide arm, end of study
Source sentences
Summary
Decreases in A1C were: 7.6 to 6.2% for Iglar + GLP-1, 7.5 to 6.6% for Iglar, and 7.5 to 6.4% for GLP-1.
3 context sentences(design, population, supporting numbers)
Summary · context
Open-label, randomized, parallel-arm study of adults with type 2 diabetes naïve to both insulin and glucagon-like peptide 1 (GLP-1) agonist who were not at A1C goal despite treatment with metformin.
Summary · context
Subjects were randomized to treatment with glargine (Iglar), exenatide (GLP-1), or combination of glargine and exenatide (Iglar + GLP-1).
Summary · context
At midpoint, those not at A1C target had the second medication added; those on Iglar + GLP-1 continued therapy optimization.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3099543302
03HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, glargine plus exenatide reached A1C targets faster, at 14 to 16 weeks.
In plain wordsIn adults with type 2 diabetes, glargine plus exenatide reached A1C targets faster than single-drug starting regimens.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTime to A1C target
Study
n: not reported in source
Comparator
single-drug starting regimens
Outcome group
Glycemic control · Metabolic and weight
Measurements
Time to A1C target
14 to 16 weeks
glargine plus exenatide
Source sentences
Summary
Iglar + GLP-1 achieved A1C targets faster (14 to 16 weeks) but had more hypoglycemia.
3 context sentences(design, population, supporting numbers)
Summary · context
Open-label, randomized, parallel-arm study of adults with type 2 diabetes naïve to both insulin and glucagon-like peptide 1 (GLP-1) agonist who were not at A1C goal despite treatment with metformin.
Summary · context
Subjects were randomized to treatment with glargine (Iglar), exenatide (GLP-1), or combination of glargine and exenatide (Iglar + GLP-1).
Summary · context
At midpoint, those not at A1C target had the second medication added; those on Iglar + GLP-1 continued therapy optimization.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3099543303
04HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes, glargine plus exenatide had more hypoglycemia than single-drug starting regimens.
In plain wordsIn adults with type 2 diabetes, glargine plus exenatide was linked to more low blood glucose than single-drug starting regimens.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHypoglycemia with combination
Study
n: not reported in source
Comparator
single-drug starting regimens
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Iglar + GLP-1 achieved A1C targets faster (14 to 16 weeks) but had more hypoglycemia.
3 context sentences(design, population, supporting numbers)
Summary · context
Open-label, randomized, parallel-arm study of adults with type 2 diabetes naïve to both insulin and glucagon-like peptide 1 (GLP-1) agonist who were not at A1C goal despite treatment with metformin.
Summary · context
Subjects were randomized to treatment with glargine (Iglar), exenatide (GLP-1), or combination of glargine and exenatide (Iglar + GLP-1).
Summary · context
At midpoint, those not at A1C target had the second medication added; those on Iglar + GLP-1 continued therapy optimization.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3099543304
05HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes, hypoglycemia increased slightly in all arms, including initial exenatide and combination regimens.
In plain wordsIn adults with type 2 diabetes, low blood glucose increased slightly in all arms, including exenatide regimens.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHypoglycemia over time
Study
n: not reported in source
Comparator
baseline
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Hypoglycemia rates increased slightly for all arms.
3 context sentences(design, population, supporting numbers)
Summary · context
Open-label, randomized, parallel-arm study of adults with type 2 diabetes naïve to both insulin and glucagon-like peptide 1 (GLP-1) agonist who were not at A1C goal despite treatment with metformin.
Summary · context
Subjects were randomized to treatment with glargine (Iglar), exenatide (GLP-1), or combination of glargine and exenatide (Iglar + GLP-1).
Summary · context
At midpoint, those not at A1C target had the second medication added; those on Iglar + GLP-1 continued therapy optimization.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3099543305
06HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, weight loss occurred in all regimens, including those containing exenatide.
In plain wordsIn adults with type 2 diabetes, all regimens produced weight loss, including those containing exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight loss across regimens
Study
n: not reported in source
Comparator
baseline
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Weight loss was achieved in all regimens including GLP-1.
3 context sentences(design, population, supporting numbers)
Summary · context
Open-label, randomized, parallel-arm study of adults with type 2 diabetes naïve to both insulin and glucagon-like peptide 1 (GLP-1) agonist who were not at A1C goal despite treatment with metformin.
Summary · context
Subjects were randomized to treatment with glargine (Iglar), exenatide (GLP-1), or combination of glargine and exenatide (Iglar + GLP-1).
Summary · context
At midpoint, those not at A1C target had the second medication added; those on Iglar + GLP-1 continued therapy optimization.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3099543306
07HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the initial exenatide arm reduced glucose variability more than the initial glargine arm.
In plain wordsIn adults with type 2 diabetes, the initial exenatide regimen reduced glucose variability more than the initial glargine regimen.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlucose variability
Study
n: not reported in source
Comparator
initial glargine arm
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Glucose variability was not reduced to the same extent in the Iglar arm as the GLP-1 arm.
3 context sentences(design, population, supporting numbers)
Summary · context
Open-label, randomized, parallel-arm study of adults with type 2 diabetes naïve to both insulin and glucagon-like peptide 1 (GLP-1) agonist who were not at A1C goal despite treatment with metformin.
Summary · context
Subjects were randomized to treatment with glargine (Iglar), exenatide (GLP-1), or combination of glargine and exenatide (Iglar + GLP-1).
Summary · context
At midpoint, those not at A1C target had the second medication added; those on Iglar + GLP-1 continued therapy optimization.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3099543307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.